Investigated for treating COVID-19.
- TRADE NAMES: Gleevec (Novartis); Glivec
- INDICATIONS: Chronic myeloid leukemia
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Bcr-Abl tyrosine kinase inhibitor / (Breakpoint cluster region Abelson (Bcr-Abl) tyrosine kinase inhibitor, Biologic, Tyrosine kinase inhibitor
- HALF-LIFE: 18 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Amlodipine, Anisindione, Anticoagulants, Aprepitant, Atorvastatin, Barbiturates, Benzodiazepines, Butabarbital, Carbamazepine, Chlordiazepoxide, Clarithromycin, Clonazepam, Clorazepate, Corticosteroids, Cyclosporine, Dexamethasone, Diazepam, Dicumarol, Efavirenz, Erythromycin, Ethotoin, Felodipine, Flurazepam, Fluvastatin, Fosphenytoin, Isradipine, Itraconazole, Ketoconazole, Lorazepam, Lovastatin, Mephenytoin, Mephobarbital, Midazolam, Mifepristone, Neratinib, Nicardipine, Nifedipine, Nimodipine, Nisoldipine, Olaparib, Oxazepam, Oxcarbazepine, Pentobarbital, Phenobarbital, Phenytoin, Pimozide, Pravastatin, Primidone, Quazepam, Rifampin, Rifapentine, Safinamide, Secobarbital, Simvastatin, St John's Wort, Tafamidis meglumine, Temazepam, Voriconazole, Warfarin
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of imatinib in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 11/26/2024
